PTU - Polskie Towarzystwo Urologiczne
list of articles:

Diagnostic workup of the urinary tract diseases with the use of fluorescent probes and in situ hybridization techniques
Article published in Urologia Polska 2007/60/4.


Tomasz Drewa, Zbigniew Wolski, Joanna Łysik
Katedra i Klinika Urologii Ogólnej, Onkologicznej i Dziecięcej, Collegium Medicum Uniwersytetu Mikołaja Kopernika w Bydgoszczy
Zakład Inżynierii Tkankowej, Katedra Biologii Medycznej, Collegium Medicum Uniwersytetu Mikołaja Kopernika w Bydgoszczy
Katedra i Klinika Onkologii i Brachyterapii, Collegium Medicum Uniwersytetu Mikołaja Kopernika w Bydgoszczy


bladder cancer, renal cancer, Wilms' tumor, prostate cancer, testicular cancer, infertility


Introduction.The principles of fluorescence microscopy, DNA probe hybridization technique to the target place and fluorescence in situ hybridization (FISH) were presented in this review. Different FISH techniques were shown together with their potential applications.

Material and method. Medline was searched for the material for analysis. The applications of FISH in detection and diagnostic workup of the transitional cell carcinoma (TCC), prostate cancer, renal and testicular tumors and sexual differentiation together with infertility management were presented and discussed.

Results. The FISH technique will be applicable in TCC, prostate cancer and Wilms’ tumor diagnostic workup. The FISH technique can be used in the histological analysis of hybrid renal tumors. FISH analysis is nowadays wildly used in the research and cytogenetic studies in consulting on fertility.

Conclusions. The FISH technique is a time consuming procedure. Cellular slides should be prepared and sometimes in vitro culture is needed. The price of the single test is high. The above mentioned obstacles cause that process of introducing FISH technique into clinical practice is slow.


  1. Drewa T: Wpływ nowych kompleksów platyny na przeżywalność i apoptozę
  2. komórek czerniaka B16 i ClS91 in vitro. Rozprawa doktorska. Akademia Medyczna w Bydgoszczy, 1999, str. 35-38.
  3. Drewa G, Ferenc T (red.): Genetyka dla studentów i lekarzy. Wyd 2, Volumen, Urban & Partner, Wrocław, Warszawa, 2003, str. 453-455.
  4. Clark MS, Wall WJ (red.): Chromosomes. The complex code. Alden Press, Oxford, 1996, str. 80-92.
  5. Sokolova IA, Halling KC, Jenkins RB et al: The development of a multitarget,
  6. multi-color fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000, 3, 116-123.
  7. Halling KC, King W, Sokolova IA et al: A comparison of cytology and fluorescence
  8. in situ hybridization for the detection of urothelial carcinoma. J Urol 2000, 164, 1768-1775.
  9. Halling KC, King W, Sokolova IA et al: A comparison of BTA stat, hemoglobin
  10. dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002, 167, 2001-2006.
  11. Kipp BR, Campion MB, Coffman E et al: An evaluation of ThinPrep UroCyte filters for the preparation of slides for fluorescence in situ hybridization.
  12. Diagn Cytopathol 2006, 34, 479-484.
  13. Friedrich MG, Toma MI, Hellstern A et al: Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003, 92, 911-914.
  14. Kipp BR, Karnes RJ, Brankley SM et al: Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005, 173, 401-404.
  15. Krause FS, Rauch A, Schrott KM, Engehausen DG: Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence
  16. in situ hybridization as-says? World J Urol 2006, 24, 418-422.
  17. Pycha A, Lodde M, Comploj E et al: Intermediate-risk urothelial carcinoma: an unre-solved problem? Urology 2004, 63, 472-476.
  18. Dotan ZA, Dotan A, Ramon J, Avivi L: Altered mode of allelic replication accompa-nied by aneuploidy in peripheral blood lymphocytes of prostate cancer patients. Int J Cancer 2004, 111, 60-66.
  19. Tinzl M, Marberger M, Horvath S, Chypre: C.DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 2004, 46, 182-186.
  20. Das K, Lau W, Sivaswaren C et al: Chromosomal changes in prostate cancer: a fluo-rescence in situ hybridization study. Clin Genet 2005, 68, 40-47.
  21. Brown RS, Edwards J, Dogan A et al: Amplification of the androgen receptor
  22. gene in bone metastases from hormone-refractory prostate cancer. J Pathol 2002, 198, 237-244.
  23. Bastacky S, Cieply K, Sherer C et al: Use of interphase fluorescence in situ hybridiza-tion in prostate needle biopsy specimens with isolated high-grade
  24. prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma
  25. on follow-up biopsy. Hum Pathol 2004, 35, 281-289.
  26. Alcaraz A, Corral JM, Ribal MJ et al: Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer. BJU Int 2004, 94, 407-411.
  27. Karan D, Lin MF, Johansson SL, Batra SK: Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 2003,103, 285-293.
  28. Ropke A, Erbersdobler A, Hammerer P: Gain of androgen receptor gene copies in pri-mary prostate cancer due to X chromosome polysomy. Prostate 2004, 59, 59-68.
  29. Al-Saleem T, Balsara BR, Liu Z et al: Renal oncocytoma with loss of chromosomes
  30. Y and 1 evolving to papillary carcinoma in connection with gain of chromosome 7. Coincidence or progression? Cancer Genet Cytogenet 2005, 163, 81-85.
  31. Corless CL, Aburatani H, Fletcher JA et al: Papillary renal cell carcinoma: quantita-tion of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy. Diagn Mol Pathol 1996, 5, 53-64.
  32. Receveur AO, Couturier J, Molinie V et al: Characterization of quantitative chromo-somal abnormalities in renal cell carcinomas by interphase four-
  33. color fluorescence in situ hybridization. Cancer Genet Cytogenet 2005, 158, 110-118.
  34. Sanjmyatav J, Rubtsov N, Starke H et al: Identification of tumor entities of renal cell carcinoma using interphase fluorescence in situ hybridization. J Urol 2005, 174, 731-735.
  35. Izumi H, Hara T, Oga A et al: High telomerase activity correlates with the stabilities of genome and DNA ploidy in renal cell carcinoma. Neoplasia 2002, 4, 103-111.
  36. Gisselsson D, Gorunova L, Hoglund M et al: Telomere shortening and mitotic dysfunction generate cytogenetic heterogeneity in a subgroup of renal cell carcinomas. Br J Cancer 2004, 91, 327-332.
  37. Aalfs CM, Fantes JA, Wenniger-Prick LJ et al: Tandem duplication of 11p12-
  38. p13 in a child with borderline development delay and eye abnormalities: dose effect of the PAX6 gene product? Am J Med Genet 1997, 73, 267-271.
  39. Muto R, Yamamori S, Ohashi H, Osawa M: Prediction by FISH analysis of the occur-rence of Wilms tumor in aniridia patients. Am J Med Genet 2002,108, 285-289.
  40. Soule S, Baldridge L, Kirkpatrick K et al: HER-2/neu expression in germ cell tumours. J Clin Pathol 2002, 55, 656-658.
  41. Verdorfer I, Rogatsch H, Tzankov A et al: Molecular cytogenetic analysis of human spermatocytic seminomas. J Pathol 2004, 204, 277-281.
  42. Pena-Alonso R, Nieto K, Alvarez R et al: Distribution of Y-chromosome-bearing cells in gonadoblastoma and dysgenetic testis in 45,X/46,XY infants. Mod Pathol 2005, 18, 439-445.
  43. Gimelli G, Giorda R, Beri S et al: A 46,X,inv(Y) young woman with gonadal dysgenesis and gonadoblastoma: cytogenetics, molecular, and methylation
  44. studies. Am J Med Genet A 2006, 140, 40-45.
  45. Egozcue J, Sarrate Z, Codina-Pascual M et al: Meiotic abnormalities in infertile males. Cytogenet Genome Res 2005, 111, 337-342.
  46. Gianaroli L, Magli MC, Ferraretti AP: Sperm and blastomere aneuploidy detection in reproductive genetics and medicine. J Histochem Cytochem 2005, 53, 261-267.
  47. Sun F, Ko E, Martin RH: Is there a relationship between sperm chromosome abnor-malities and sperm morphology? Reprod Biol Endocrinol 2006, 25, 1.


Tomasz Drewa
Zakład Inżynierii Tkankowej
ul. Karłowicza 24
85-092 Bydgoszcz
tel. (052) 585 37 37